Structured event evidence
| Event | Status | Section | Frequency | Evidence | Source page |
|---|---|---|---|---|---|
| Elevated serum calcium | Listed | — | Not stated | Observed with excessive use of topical calcipotriene. | — |
| greater sensitivity of older individuals | Under review | — | Not stated | The label states that greater sensitivity of older individuals cannot be ruled out. | — |
| hypersensitivity | Listed | — | Not stated | Contraindication for patients with a history of hypersensitivity to any component of the preparation. | — |
| potential risk to the fetus | Under review | — | Not stated | Pregnancy; use during pregnancy is conditioned on the potential benefit justifying the potential fetal risk. | — |
| Rash, pruritus, dermatitis and worsening of psoriasis | Listed | — | Not stated | Reported in 1 to 10% of patients. | — |
| Reversible elevation of serum calcium | Listed | — | Not stated | The label reports this elevation with use of topical calcipotriene. | — |
| skin irritation | Listed | — | Not stated | Reported in approximately 10-15% of patients in controlled clinical trials. | — |
| systemic adverse effects | Listed | — | Not stated | Pediatric patients are stated to be at greater risk than adults of systemic adverse effects when treated with topical medication. | — |
| transient irritation of both lesions and surrounding uninvolved skin | Listed | — | Not stated | The label states that use of Dovonex Cream may cause this irritation. | — |
No indexed event matched this search.
A search miss is not a negative listedness finding.